BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 32305991)

  • 1. High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
    Zhou Z; Wu B; Tang X; Yang W; Zou Q; Wang H
    Med Sci Monit; 2020 Apr; 26():e922982. PubMed ID: 32305991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of Fibroblast Growth Factor Receptor (FGFR) Family Genes in Breast Cancer by Integrating Online Databases and Bioinformatics.
    Zhou Z; Wu B; Tang X; Ke R; Zou Q
    Med Sci Monit; 2020 May; 26():e923517. PubMed ID: 32381997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying hepatocellular carcinoma-related hub genes by bioinformatics analysis and CYP2C8 is a potential prognostic biomarker.
    Li C; Zhou D; Jiang X; Liu M; Tang H; Mei Z
    Gene; 2019 May; 698():9-18. PubMed ID: 30825595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioinformatics Analysis Identified Key Molecular Changes in Bladder Cancer Development and Recurrence.
    Chen Q; Hu J; Deng J; Fu B; Guo J
    Biomed Res Int; 2019; 2019():3917982. PubMed ID: 31828101
    [No Abstract]   [Full Text] [Related]  

  • 6. Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    Liu J; Yang X; Zhang L; Yang B; Rao W; Li M; Dai N; Yang Y; Qian C; Zhang L; Xiao H; Wang D
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2299-2310. PubMed ID: 32556504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
    Zhang L; Sun L; Zhang B; Chen L
    Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Value of miR-101-3p and Biological Analysis of its Prospective Targets in Breast Cancer: A Study Based on The Cancer Genome Atlas (TCGA) and Bioinformatics.
    Li CY; Xiong DD; Huang CQ; He RQ; Liang HW; Pan DH; Wang HL; Wang YW; Zhu HW; Chen G
    Med Sci Monit; 2017 Apr; 23():1857-1871. PubMed ID: 28416776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of aberrantly methylated differentially expressed genes in breast cancer by integrated bioinformatics analysis.
    Yi L; Luo P; Zhang J
    J Cell Biochem; 2019 Sep; 120(9):16229-16243. PubMed ID: 31081184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
    Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
    J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis.
    Lu X; Gao C; Liu C; Zhuang J; Su P; Li H; Wang X; Sun C
    Pathol Res Pract; 2019 Aug; 215(8):152475. PubMed ID: 31178227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
    Wong CM; Wei L; Law CT; Ho DW; Tsang FH; Au SL; Sze KM; Lee JM; Wong CC; Ng IO
    Hepatology; 2016 Feb; 63(2):474-87. PubMed ID: 26481868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis.
    Fang E; Zhang X
    Cancer Biomark; 2017 Dec; 21(1):373-381. PubMed ID: 29081411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
    Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated bioinformatics analysis reveals key candidate genes and pathways in breast cancer.
    Wang Y; Zhang Y; Huang Q; Li C
    Mol Med Rep; 2018 Jun; 17(6):8091-8100. PubMed ID: 29693125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer.
    Xu W; Wang Y; Wang Y; Lv S; Xu X; Dong X
    Int J Mol Med; 2019 Aug; 44(2):390-404. PubMed ID: 31198978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentially Expressed Gene Screening, Biological Function Enrichment, and Correlation with Prognosis in Non-Small Cell Lung Cancer.
    Huang H; Huang Q; Tang T; Zhou X; Gu L; Lu X; Liu F
    Med Sci Monit; 2019 Jun; 25():4333-4341. PubMed ID: 31181055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
    Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
    Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis.
    Wen P; Chidanguro T; Shi Z; Gu H; Wang N; Wang T; Li Y; Gao J
    Mol Med Rep; 2018 Aug; 18(2):1538-1550. PubMed ID: 29845250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
    Liu X; Liu X; Li J; Ren F
    Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.